Research shows that a balanced, diverse gastrointestinal microbiome is crucial for well-being.
In a recent webinar, Dr. Stephen Olmstead helped us to see the microbiome as a distinct organ, essential for health.
Dr. Olmstead not only has greater than 30 years of experience practicing and teaching medicine, he is the Chief Science Officer of ProThera Inc. and develops innovative probiotics and prebiotics for nutraceutical use. He shared this insight with us in an information-packed presentation on the use of probiotics and prebiotics to improve disease outcomes. Here are just a few of the highlights from that presentation.
None of us would argue that the liver is an important visceral organ. But how many of us realize the equal importance of our gastrointestinal microbiome acting as an organ as well? The intestinal microbiome modulates many immune and metabolic responses. Its far-reaching health implications are widely underestimated.
Research shows promise that we can influence the microbiome and improve long-term health. Many of us know that probiotics are helpful, but most of us don't realize the impact that dietary changes can have as well. Many factors can be used to modulate the microbiome, and the outcome and courses of many diseases can be influenced with the right "recipe."
With all of this new information about the use of probiotics and prebiotics, how do we apply this to targeted treatment of specific diseases? After compiling the evidence, Dr. Olmstead outlines his recommendations for treatment of two challenging GI disorders: Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).
Are probiotics ever harmful? How much is too much? Numerous questions surround the use of probiotics and prebiotics. Some of the most important questions are finally answered as Dr. Olmstead compiles several key points to address probiotic therapy.
Not only can we make changes to improve our health, but with targeted treatment strategies, we can significantly improve disease outcomes. Join Dr. Stephen Olmstead as he outlines more treatment strategies that can alter the microbiome by viewing his entire webinar "Modulating the Gut Microbiome & the Role of Probiotics & Prebiotics". Use the links below to find information, descriptions, and sample reports of Genova's extensive GI-testing product line.
The Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) offers unique insight into overall gastrointestinal health by assessing advanced biomarkers.